BioMarin Pharmaceutical Inc.

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

10 Sep 2019 09:45:06 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

09 Sep 2019 09:50:21 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

15 Aug 2019 09:45:01 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

14 Aug 2019 09:45:02 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

13 Aug 2019 09:45:00 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

12 Aug 2019 11:44:24 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

06 Aug 2019 10:30:54 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

05 Aug 2019 10:11:20 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

02 Aug 2019 09:45:02 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

31 Jul 2019 15:08:40 By NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

30 Jul 2019 09:47:08 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 Oct 2018 10:48:59 By NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 Dec 2016 08:29:22 By Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 Nov 2016 08:30:46 By Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 Oct 2016 16:03:46 By Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 Oct 2016 17:01:21 By Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 Oct 2016 16:01:29 By Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 Oct 2016 08:31:09 By Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 Sep 2016 08:54:15 By Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 Sep 2016 08:38:09 By Nasdaq GlobeNewswire